22 April: Biogen withdraws marketing authorisation application for aducanumab

On 22 April 2022, Biogen announced that it had notified the European Medicines Agency about the withdrawal of its marketing authorisation application for aducanumab, for the treatment of early Alzheimer’s disease.

Read more »
Rate: 12345 (0) | Facebook Twitter
26 April: Alzheimer Europe hosts Academy session on giving a voice to people with dementia

On 26 April 2022, Alzheimer Europe held an online session of its popular Alzheimer's Association Academy series, bringing together representatives of its member organisations, the European Working Group of People with Dementia, pharmaceutical companies and researchers. The topic for this session was "giving a voice to people with dementia".

Read more »
Rate: 12345 (0) | Facebook Twitter
28 April: Alzheimer Europe signs Memorandum of Understanding with European Association of Service Providers for Persons with Disabilities

On 28 April 2022, Alzheimer Europe and the European Association of Service Providers for Persons with Disabilities (EASPD) signed a Memorandum of Understanding, to provide the basis for future collaboration.

Read more »
Rate: 12345 (0) | Facebook Twitter
29 April: Call for abstracts for the 32nd Alzheimer Europe Conference closing soon!

The call for abstracts for the 32nd Alzheimer Europe Conference (#32AEC), "Building Bridges”, which will take place in Bucharest, Romania, from 17 to 19 October 2022, will soon close. The deadline for submissions is 15 May 2022.

Read more »
Rate: 12345 (0) | Facebook Twitter